Close

Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH)

Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH), US Department of Health & Human Services, USA

BIO 2016 Special 301 Submission

The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the 2016 Special 301 Submission. 

BIO President and CEO Jim Greenwood to Chair BIO Ventures for Global Health Board of Directors

BVGH engages leading biopharmaceutical companies in partnerships and programs to address challenging global health issues

BIO Comments on Draft Patents (Amendment) Rule 2015

The Biotechnology Industry Organization (BIO) greatly appreciates the opportunity to provide comments/suggestions of the stakeholders on the Draft Patents (Amendment) Rules 2015 published by the Ministry of Commerce & Industry.

BIO Joins Coalition Cautioning Against Further Restructuring of Japan’s Pharmaceutical Pricing Structure

Today BIO joined a coalition of organizations urging the Government of Japan to maintain the established reimbursement pricing structure for pharmaceuticals and medical devices.

BIO 2015 Special 301 Submission

The Biotechnology Industry Organization (BIO) appreciates the opportunity to participate in the Special 301 process and is hopeful that our contribution will assist the United States Trade Representative’s (USTR) efforts in preserving strong intellectual property protections for United States’ companies internationally. BIO appreciates the opportunity to comment on 2015 Special 301 Review: Identification of Countries Under Section 182 of the Trade Act of 1974: Request for Public Comment and Announcement of Public Hearing.

Building a World-Class Innovative Therapeutic Biologics Industry in China

Therapeutic biologics are an opportunity to address unmet patient needs, drive innovation, and assist China's transformation into a knowledge-intensive economy.

BIO Comments on TTIP Negotiations

The TTIP represents a profoundly important opportunity to advance progress in these areas. The following comments represent BIO’s initial suggestions for the formulation of negotiating objectives relevant to biotechnology.  

Transatlantic Trade and Investment Partnership

BIO appreciates the opportunity to respond to the Request for Comments issued by the U.S. Trade Representative on objectives to be pursued in the negotiation of a Transatlantic Trade and Investment Partnership (TTIP) agreement. 

2013 Special 301 Submission: BIO Provides Input on Biotech IP Challenges Around the Globe

Biotechnology companies provide unique benefits to the United States and the world. In the health care sector alone, the industry has developed and commercialized more than 300 biotechnology drugs and diagnostics and there are over 400 products in the pipeline.